As a young, dynamic and creative molecular diagnostics company, we have specialized in simple and rapid solutions for the diagnosis of severe infectious diseases in hospitalized patients. We help to combat infections effectively and detect antibiotic resistance at an early stage.
Curetis Publishes Business and Financial Update for the First Nine Months of 2017
Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge
Association for Molecular Pathology, Salt Lake City, UT, USA - November 16 to 19, 2017
Pneumologie, Update Refresher 2017 - Zürich, Switzerland - November, 16, 2017